A 56-year-old man is brought to the clinic by his wife for complaints of progressive weakness for the past 3 months. He reports difficulty eating, especially when chewing foods like steak. The wife complains that he has been “out of it lately and has been forgetting my birthday." His past medical history is significant for celiac disease, for which he eats a gluten-free diet. He reports that he stepped on a nail last week, but the nail did not seem rusty so he just washed his feet afterward. His wife reports that he has been up to date on his tetanus vaccinations. Physical examination demonstrates weakness and fasciculations of the left upper extremity along with spastic clonus of the left ankle. The patient denies gait disturbances, vision or hearing changes, headaches, nausea/vomiting, gastrointestinal disturbances, or incontinence. What is best next step in terms of management for this patient?
Q282
A researcher is studying the circulating factors that are released when immune cells are exposed to antigens. Specifically, she is studying a population of CD2+ cells that have been activated acutely. In order to determine which factors are secreted by these cells, she cultures the cells in media and collects the used media from these plates after several days. She then purifies a small factor from this media and uses it to stimulate various immune cell types. She finds that this factor primarily seems to increase the growth and prolong the survival of other CD2+ cells. Which of the following is most likely the factor that was purified by this researcher?
Q283
A 20-year-old man comes to the physician because of recurrent episodes of shortness of breath and a nonproductive cough for the past 4 months. He has two episodes per week, which resolve spontaneously with rest. Twice a month, he wakes up at night with shortness of breath. His pulse is 73/min, respirations are 13/min, and blood pressure is 122/70 mm Hg. Pulse oximetry on room air shows an oxygen saturation of 98%. Physical examination shows no abnormalities. Spirometry shows an FVC of 95%, an FEV1:FVC ratio of 0.85, and an FEV1 of 81% of predicted. Which of the following is the most appropriate initial pharmacotherapy?
Q284
A 68-year-old woman comes to the physician for a follow-up examination. Three months ago, she underwent heart transplantation for restrictive cardiomyopathy and was started on transplant rejection prophylaxis. Her pulse is 76/min and blood pressure is 148/82 mm Hg. Physical examination shows enlargement of the gum tissue. There is a well-healed scar on her chest. Serum studies show hyperlipidemia. The physician recommends removing a drug that decreases T cell activation by inhibiting the transcription of interleukin-2 from the patient's treatment regimen and replacing it with a different medication. Which of the following drugs is the most likely cause of the adverse effects seen in this patient?
Q285
A 63-year-old African American man presents to the physician for a follow-up examination. He has a history of chronic hypertension and type 2 diabetes mellitus. He has no history of coronary artery disease. His medications include aspirin, hydrochlorothiazide, losartan, and metformin. He exercises every day and follows a healthy diet. He does not smoke. He consumes alcohol moderately. There is no history of chronic disease in the family. His blood pressure is 125/75 mm Hg, which is confirmed on a repeat measurement. His BMI is 23 kg/m2. The physical examination shows no abnormal findings. The laboratory test results show:
Serum
HbA1C 6.9%
Total cholesterol 176 mg/dL
Low-density lipoprotein (LDL-C) 105 mg/dL
High-density lipoprotein (HDL-C) 35 mg/dL
Triglycerides 175 mg/dL
The patient's 10-year risk of cardiovascular disease (CVD) is 18.7%. Lifestyle modifications including diet and exercise have been instituted. Which of the following is the most appropriate next step in pharmacotherapy?
Q286
A 60-year-old man comes to the physician for the evaluation of nausea over the past week. During this period, he has also had several episodes of non-bloody vomiting. Last month, he was diagnosed with stage II Hodgkin lymphoma and was started on adriamycin, bleomycin, vinblastine, and dacarbazine. His temperature is 37°C (98.6°F), pulse is 95/min, and blood pressure is 105/70 mm Hg. Physical examination shows cervical lymphadenopathy. The liver is palpated 1 to 2 cm below the right costal margin, and the spleen is palpated 2 to 3 cm below the left costal margin. The remainder of the examination shows no abnormalities. The patient is started on an appropriate medication. Two weeks later, he develops headaches and states that his last bowel movement was 4 days ago. The patient was most likely treated with which of the following medications?
Q287
An 18-year-old woman presents to the emergency department with a complaint of severe abdominal pain for the past 6 hours. She is anorexic and nauseous and has vomited twice since last night. She also states that her pain initially began in the epigastric region, then migrated to the right iliac fossa. Her vital signs include a respiratory rate of 14/min, blood pressure of 130/90 mm Hg, pulse of 110/min, and temperature of 38.5°C (101.3°F). On abdominal examination, there is superficial tenderness in her right iliac fossa, rebound tenderness, rigidity, and abdominal guarding. A complete blood count shows neutrophilic leukocytosis and a shift to the left. Laparoscopic surgery is performed and the inflamed appendix, which is partly covered by a yellow exudate, is excised. Microscopic examination of the appendix demonstrates a neutrophil infiltrate of the mucosal and muscular layers with extension into the lumen. Which of the following chemical mediators is responsible for pain in this patient?
Q288
A 72-year-old man presents to the emergency department with a 1 hour history of bruising and bleeding. He says that he fell and scraped his knee on the ground. Since then, he has been unable to stop the bleeding and has developed extensive bruising around the area. He has a history of gastroesophageal reflux disease, hypertension, and atrial fibrillation for which he is taking an oral medication. He says that he recently started taking omeprazole for reflux. Which of the following processes is most likely inhibited in this patient?
Q289
A 55-year-old man comes to the physician because of a 2-month history of gradually worsening pain and burning in his feet that is impairing his ability to sleep. He also has a non-healing, painless ulcer on the bottom of his right toe, which has been progressively increasing in size despite the application of bandages and antiseptic creams at home. He has a 7-year history of type II diabetes mellitus treated with oral metformin. He also has narrow-angle glaucoma treated with timolol eye drops and chronic back pain due to a motorcycle accident a few years ago, which is treated with tramadol. Vital signs are within normal limits. Physical examination shows a 3-cm, painless ulcer on the plantar surface of the right toe. The ulcer base is dry, with no associated erythema, edema, or purulent discharge. Neurological examination shows loss of touch, pinprick sensation, proprioception, and vibration sense of bilateral hands and feet. These sensations are preserved in the proximal portions of the limbs. Muscle strength is normal. Bilateral ankle reflexes are absent. A diabetic screening panel is done and shows a fasting blood sugar of 206 mg/dL. An ECG shows a left bundle branch block. Which of the following is the most appropriate next step in the management of this patient's pain?
Q290
A 28-year-old woman presents with increased facial hair growth. She says she noticed a marked growth and darkening of hair on her face and feels embarrassed. Past medical history is significant for asthma, well-controlled by medication, and epilepsy diagnosed 6 months ago, managed with phenytoin. Her other medications are albuterol, beclomethasone, a daily multivitamin, and a garlic supplement. The patient denies any smoking history, alcohol or recreational drug use. Family history is significant for asthma in her father. Review of systems is positive for occasional diplopia. Her pulse is 75/min, respiratory rate is 15 /min, and blood pressure is 110/76 mm Hg. Her body mass index (BMI) is 24 kg/m2. On physical examination, she appears healthy in no apparent distress. There are excessive facial hair growth and enlarged gums. The remainder of the examination is unremarkable. Which of the following medications is most likely responsible for this patient's symptoms?
Autonomic/CV Drugs US Medical PG Practice Questions and MCQs
Question 281: A 56-year-old man is brought to the clinic by his wife for complaints of progressive weakness for the past 3 months. He reports difficulty eating, especially when chewing foods like steak. The wife complains that he has been “out of it lately and has been forgetting my birthday." His past medical history is significant for celiac disease, for which he eats a gluten-free diet. He reports that he stepped on a nail last week, but the nail did not seem rusty so he just washed his feet afterward. His wife reports that he has been up to date on his tetanus vaccinations. Physical examination demonstrates weakness and fasciculations of the left upper extremity along with spastic clonus of the left ankle. The patient denies gait disturbances, vision or hearing changes, headaches, nausea/vomiting, gastrointestinal disturbances, or incontinence. What is best next step in terms of management for this patient?
A. Tetanus immunoglobulin and vaccine
B. Riluzole (Correct Answer)
C. Vitamin B12
D. Levodopa
E. Donepezil
Explanation: ***Riluzole***
- The patient's presentation with **progressive weakness**, **difficulty chewing**, **fasciculations**, and **spastic clonus** strongly suggests **amyotrophic lateral sclerosis (ALS)**, a motor neuron disease.
- **Riluzole** is a neuroprotective drug approved for ALS that can modestly extend survival and delay the need for tracheostomy.
*Tetanus immunoglobulin and vaccine*
- Although the patient stepped on a nail, his extensive neurological symptoms are **not consistent with tetanus**, which typically causes muscle spasms and rigidity.
- The patient's wife states he is **up to date on tetanus vaccinations**, making tetanus less likely, and the neurological signs point elsewhere.
*Vitamin B12*
- **Vitamin B12 deficiency** can cause neurological symptoms like peripheral neuropathy, cognitive changes, and gait disturbances, but it typically does **not present with fasciculations and spasticity** as seen here.
- While celiac disease increases the risk of malabsorption, the constellation of symptoms is more indicative of ALS.
*Levodopa*
- **Levodopa** is a primary treatment for **Parkinson's disease**, which involves tremors, bradykinesia, rigidity, and postural instability.
- The patient's symptoms of primarily upper motor neuron (spastic clonus) and lower motor neuron (fasciculations) signs, with absent gait disturbances, are **not typical for Parkinson's disease**.
*Donepezil*
- **Donepezil** is an acetylcholinesterase inhibitor used to treat **Alzheimer's disease** and other forms of dementia.
- Although the patient has some "forgetting," his predominant symptoms are **motor neuron deficits** rather than cognitive decline, making donepezil an inappropriate first-line treatment for his primary condition.
Question 282: A researcher is studying the circulating factors that are released when immune cells are exposed to antigens. Specifically, she is studying a population of CD2+ cells that have been activated acutely. In order to determine which factors are secreted by these cells, she cultures the cells in media and collects the used media from these plates after several days. She then purifies a small factor from this media and uses it to stimulate various immune cell types. She finds that this factor primarily seems to increase the growth and prolong the survival of other CD2+ cells. Which of the following is most likely the factor that was purified by this researcher?
A. Interleukin-2 (Correct Answer)
B. Interleukin-3
C. Interleukin-4
D. Interleukin-5
E. Interleukin-1
Explanation: ***Interleukin-2***
- **Interleukin-2 (IL-2)** is a crucial cytokine for the **growth**, **proliferation**, and **survival** of T lymphocytes, which are CD2+ cells.
- Activated T cells, like the acute CD2+ cells in the scenario, are a primary source of IL-2, and IL-2 acts in an **autocrine** and **paracrine** fashion to stimulate other T cells.
*Interleukin-3*
- **Interleukin-3 (IL-3)** primarily stimulates the growth and differentiation of **hematopoietic stem cells** and progenitors, not specifically mature CD2+ cells.
- It plays a role in the development of various myeloid cell lineages and mast cells, and its main effect is not confined to T cells.
*Interleukin-4*
- **Interleukin-4 (IL-4)** is critical for the differentiation of naive T helper cells into **Th2 cells** and is a key cytokine for **B cell proliferation** and **antibody class switching** to IgE.
- While it has immunomodulatory effects on T cells, its primary role is not in promoting the generalized growth and survival of other CD2+ cells.
*Interleukin-5*
- **Interleukin-5 (IL-5)** is predominantly involved in the growth, differentiation, and activation of **eosinophils**.
- It also plays a role in B cell growth and IgA production, but its effects are not primarily on universal CD2+ cell growth and survival.
*Interleukin-1*
- **Interleukin-1 (IL-1)** is a **pro-inflammatory cytokine** produced by macrophages, monocytes, and other immune cells in response to infection or injury.
- It primarily mediates **acute phase responses**, fever, and activates endothelial cells, but its main function is not to promote the growth and survival of T lymphocytes.
Question 283: A 20-year-old man comes to the physician because of recurrent episodes of shortness of breath and a nonproductive cough for the past 4 months. He has two episodes per week, which resolve spontaneously with rest. Twice a month, he wakes up at night with shortness of breath. His pulse is 73/min, respirations are 13/min, and blood pressure is 122/70 mm Hg. Pulse oximetry on room air shows an oxygen saturation of 98%. Physical examination shows no abnormalities. Spirometry shows an FVC of 95%, an FEV1:FVC ratio of 0.85, and an FEV1 of 81% of predicted. Which of the following is the most appropriate initial pharmacotherapy?
A. Terbutaline inhaler
B. Mometasone inhaler and oral zafirlukast
C. Oral montelukast sodium
D. Fluticasone inhaler (Correct Answer)
E. Budesonide and formoterol inhaler
Explanation: **Fluticasone inhaler**
- The patient presents with symptoms consistent with **persistent asthma** (symptoms >2 times/week and nighttime awakenings >2 times/month).
- **Inhaled corticosteroids** like fluticasone are the preferred initial **controller therapy** for persistent asthma due to their potent **anti-inflammatory effects**.
*Terbutaline inhaler*
- Terbutaline is a **short-acting beta-agonist (SABA)**, primarily used as a **rescue medication** for acute asthma symptoms.
- While it would relieve acute symptoms, it does not address the underlying inflammation in persistent asthma and is not appropriate for **monotherapy** as initial pharmacotherapy in this context.
*Mometasone inhaler and oral zafirlukast*
- This combination includes an **inhaled corticosteroid (mometasone)** and a **leukotriene receptor antagonist (zafirlukast)**.
- While appropriate for more severe or uncontrolled asthma, starting with a **single inhaled corticosteroid** is the recommended initial step for **persistent asthma** before adding a second-line agent.
*Oral montelukast sodium*
- Montelukast is a **leukotriene receptor antagonist** used in asthma management, often as an **add-on therapy** or for patients who cannot tolerate inhaled corticosteroids.
- It is generally **less effective than inhaled corticosteroids** as initial monotherapy for persistent asthma in controlling inflammation and preventing exacerbations.
*Budesonide and formoterol inhaler*
- This is a combination of an **inhaled corticosteroid (budesonide)** and a **long-acting beta-agonist (formoterol)**.
- This combination is typically used for **moderate to severe persistent asthma** or as **maintenance and reliever therapy (MART)**, not as the initial monotherapy for mild persistent asthma.
Question 284: A 68-year-old woman comes to the physician for a follow-up examination. Three months ago, she underwent heart transplantation for restrictive cardiomyopathy and was started on transplant rejection prophylaxis. Her pulse is 76/min and blood pressure is 148/82 mm Hg. Physical examination shows enlargement of the gum tissue. There is a well-healed scar on her chest. Serum studies show hyperlipidemia. The physician recommends removing a drug that decreases T cell activation by inhibiting the transcription of interleukin-2 from the patient's treatment regimen and replacing it with a different medication. Which of the following drugs is the most likely cause of the adverse effects seen in this patient?
A. Mycophenolate mofetil
B. Azathioprine
C. Tacrolimus
D. Cyclosporine (Correct Answer)
E. Prednisolone
Explanation: ***Cyclosporine***
- The patient's symptoms of **gingival hyperplasia**, **hypertension**, and **hyperlipidemia** are classic side effects associated with cyclosporine.
- Cyclosporine is a calcineurin inhibitor that **decreases T-cell activation** by inhibiting IL-2 transcription, matching the drug description.
*Mycophenolate mofetil*
- Mycophenolate mofetil is an **antiproliferative agent** that inhibits purine synthesis, primarily affecting lymphocytes.
- Its common side effects are mainly **hematologic** (leukopenia, anemia) and **gastrointestinal** (diarrhea, nausea), not gingival hyperplasia or hypertension.
*Azathioprine*
- Azathioprine is a **purine analog** that impairs DNA synthesis and inhibits lymphocyte proliferation.
- Key side effects include **myelosuppression** (leukopenia, thrombocytopenia) and **hepatotoxicity**, which are not present here.
*Tacrolimus*
- Tacrolimus is also a **calcineurin inhibitor** that inhibits IL-2 transcription, similar to cyclosporine.
- While it can cause **hypertension** and **hyperlipidemia**, it is less commonly associated with **gingival hyperplasia** than cyclosporine.
*Prednisolone*
- Prednisolone is a **corticosteroid** used for immunosuppression, acting broadly on the immune system.
- Common side effects include **hyperglycemia**, **osteoporosis**, and **cataracts**, not specific gingival overgrowth.
Question 285: A 63-year-old African American man presents to the physician for a follow-up examination. He has a history of chronic hypertension and type 2 diabetes mellitus. He has no history of coronary artery disease. His medications include aspirin, hydrochlorothiazide, losartan, and metformin. He exercises every day and follows a healthy diet. He does not smoke. He consumes alcohol moderately. There is no history of chronic disease in the family. His blood pressure is 125/75 mm Hg, which is confirmed on a repeat measurement. His BMI is 23 kg/m2. The physical examination shows no abnormal findings. The laboratory test results show:
Serum
HbA1C 6.9%
Total cholesterol 176 mg/dL
Low-density lipoprotein (LDL-C) 105 mg/dL
High-density lipoprotein (HDL-C) 35 mg/dL
Triglycerides 175 mg/dL
The patient's 10-year risk of cardiovascular disease (CVD) is 18.7%. Lifestyle modifications including diet and exercise have been instituted. Which of the following is the most appropriate next step in pharmacotherapy?
A. Fenofibrate
B. Atorvastatin (Correct Answer)
C. Metoprolol
D. Liraglutide
E. Lisinopril
Explanation: ***Atorvastatin***
- This patient has **diabetes mellitus**, an **LDL-C of 105 mg/dL**, and an estimated **10-year CVD risk of 18.7%**. Current guidelines recommend **high-intensity statin therapy** for individuals with diabetes aged 40-75 with an LDL-C >= 70 mg/dL and a 10-year ASCVD risk of 7.5% or higher.
- Atorvastatin is a **high-intensity statin** that can significantly lower LDL-C and reduce cardiovascular event risk.
*Fenofibrate*
- **Fenofibrate** is primarily used to reduce **elevated triglyceride levels** and can increase HDL-C, but it is **not the first-line therapy** for primary prevention of cardiovascular disease in a patient with diabetes and elevated LDL-C like this one.
- Its role is usually considered in cases of **severe hypertriglyceridemia** (typically >500 mg/dL) to prevent pancreatitis, or as an adjunct to statins if triglycerides remain high, but the primary goal here is LDL reduction.
*Metoprolol*
- **Metoprolol** is a **beta-blocker** primarily used for blood pressure control, heart rate reduction, and in conditions like angina or heart failure.
- The patient's **blood pressure is well-controlled** (125/75 mmHg) with his current regimen, and there is no indication for a beta-blocker in this context for primary CVD prevention.
*Liraglutide*
- **Liraglutide** is a **GLP-1 receptor agonist** used in the management of **type 2 diabetes mellitus** to improve glycemic control and has shown cardiovascular benefits.
- However, the patient's **HbA1c of 6.9%** indicates relatively good glycemic control for a patient with diabetes, and the immediate priority for CVD prevention, given his lipid profile and risk, is LDL-C lowering with a statin.
*Lisinopril*
- **Lisinopril** is an **ACE inhibitor** commonly used for **hypertension**, heart failure, and renal protection in diabetes.
- The patient is already on **losartan**, an angiotensin receptor blocker (ARB), which serves a similar purpose, and his **blood pressure is well-controlled**, so adding lisinopril would be redundant and unnecessary for immediate CVD primary prevention.
Question 286: A 60-year-old man comes to the physician for the evaluation of nausea over the past week. During this period, he has also had several episodes of non-bloody vomiting. Last month, he was diagnosed with stage II Hodgkin lymphoma and was started on adriamycin, bleomycin, vinblastine, and dacarbazine. His temperature is 37°C (98.6°F), pulse is 95/min, and blood pressure is 105/70 mm Hg. Physical examination shows cervical lymphadenopathy. The liver is palpated 1 to 2 cm below the right costal margin, and the spleen is palpated 2 to 3 cm below the left costal margin. The remainder of the examination shows no abnormalities. The patient is started on an appropriate medication. Two weeks later, he develops headaches and states that his last bowel movement was 4 days ago. The patient was most likely treated with which of the following medications?
A. 5-HT3 antagonist (Correct Answer)
B. Cannabinoid receptor agonist
C. H1 antagonist
D. Muscarinic antagonist
E. D2 antagonist
Explanation: ***5-HT3 antagonist***
- The patient was likely treated with a **5-HT3 antagonist** due to symptoms of nausea and vomiting following chemotherapy. This class of antiemetics can cause dose-dependent **headache** and **constipation** as common side effects.
- The subsequent development of headaches and constipation (no bowel movement for 4 days) points to the known side effect profile of 5-HT3 antagonists, such as **ondansetron**.
*Cannabinoid receptor agonist*
- **Cannabinoid receptor agonists** (e.g., dronabinol) are used for chemotherapy-induced nausea and vomiting but are associated with side effects like **drowsiness**, **dizziness**, and **mood changes**, not typically headache and constipation.
- They also tend to have a slower onset of action compared to 5-HT3 antagonists.
*H1 antagonist*
- **H1 antagonists** (e.g., diphenhydramine) are used for motion sickness and mild nausea, often causing **sedation** and **anticholinergic effects** like dry mouth, blurred vision, and urinary retention.
- While they can cause constipation due to anticholinergic effects, headache is not a prominent side effect, and their primary role is not for severe chemotherapy-induced nausea.
*Muscarinic antagonist*
- **Muscarinic antagonists** (e.g., scopolamine) have antiemetic properties, particularly for motion sickness, but are not first-line for chemotherapy-induced nausea and vomiting.
- These anticholinergic drugs are associated with side effects such as **dry mouth**, **constipation**, **urinary retention**, and **blurred vision**, but they are not the most likely choice given the clinical scenario and the specific combination of headache and constipation.
*D2 antagonist*
- **D2 antagonists** (e.g., metoclopramide, prochlorperazine) are effective antiemetics but are primarily associated with **extrapyramidal symptoms** (e.g., dystonia, parkinsonism), sedation, and hyperprolactinemia.
- Although constipation can occur, the combination of headache and constipation in this context is more characteristic of 5-HT3 antagonists, which are commonly prescribed first-line for chemotherapy-induced nausea.
Question 287: An 18-year-old woman presents to the emergency department with a complaint of severe abdominal pain for the past 6 hours. She is anorexic and nauseous and has vomited twice since last night. She also states that her pain initially began in the epigastric region, then migrated to the right iliac fossa. Her vital signs include a respiratory rate of 14/min, blood pressure of 130/90 mm Hg, pulse of 110/min, and temperature of 38.5°C (101.3°F). On abdominal examination, there is superficial tenderness in her right iliac fossa, rebound tenderness, rigidity, and abdominal guarding. A complete blood count shows neutrophilic leukocytosis and a shift to the left. Laparoscopic surgery is performed and the inflamed appendix, which is partly covered by a yellow exudate, is excised. Microscopic examination of the appendix demonstrates a neutrophil infiltrate of the mucosal and muscular layers with extension into the lumen. Which of the following chemical mediators is responsible for pain in this patient?
A. IgG and complement C3b
B. Bradykinin and prostaglandin (Correct Answer)
C. 5- hydroperoxyeicosatetraenoic acid (5-HPETE) and leukotriene A4
D. Serotonin and histamine
E. Tumor necrosis factor and interleukin-1
Explanation: ***Bradykinin and prostaglandin***
- **Bradykinin** and **prostaglandins** are key inflammatory mediators that directly stimulate **nociceptors**, leading to the sensation of pain. Prostaglandins are also responsible for inducing fever.
- The patient's symptoms, including **severe abdominal pain**, fever, and local tenderness, are consistent with acute inflammation (appendicitis), where these mediators play a central role.
*IgG and complement C3b*
- **IgG** is an antibody involved in the adaptive immune response, primarily responsible for pathogen neutralization and opsonization.
- **Complement C3b** is a component of the complement system involved in opsonization and forming the membrane attack complex, but neither directly mediates pain.
*5- hydroperoxyeicosatetraenoic acid (5-HPETE) and leukotriene A4*
- **5-HPETE** is an unstable intermediate in the lipoxygenase pathway, leading to the formation of leukotrienes.
- **Leukotriene A4** is a precursor to other leukotrienes (e.g., LTB4, LTC4, LTD4) that are potent **chemotactic agents** and **bronchoconstrictors**, but they are not primary pain mediators.
*Serotonin and histamine*
- **Serotonin** is primarily involved in smooth muscle contraction, vasoconstriction, and neurotransmission; while it can modulate pain, it is not a direct primary mediator in acute appendicitis.
- **Histamine** is released by mast cells and basophils, causing vasodilation and increased vascular permeability (contributing to edema), but its role in direct pain mediation in this context is less significant than bradykinin or prostaglandins.
*Tumor necrosis factor and interleukin-1*
- **Tumor necrosis factor (TNF)** and **interleukin-1 (IL-1)** are **pro-inflammatory cytokines** that are crucial in initiating and amplifying the inflammatory response.
- While they contribute to fever and systemic symptoms of inflammation, their primary role is in cell signaling and immune cell activation rather than direct pain sensation.
Question 288: A 72-year-old man presents to the emergency department with a 1 hour history of bruising and bleeding. He says that he fell and scraped his knee on the ground. Since then, he has been unable to stop the bleeding and has developed extensive bruising around the area. He has a history of gastroesophageal reflux disease, hypertension, and atrial fibrillation for which he is taking an oral medication. He says that he recently started taking omeprazole for reflux. Which of the following processes is most likely inhibited in this patient?
A. Sulfation
B. Oxidation (Correct Answer)
C. Filtration
D. Acetylation
E. Glucuronidation
Explanation: ***Oxidation***
- The patient is taking **omeprazole**, a proton pump inhibitor, which is a known **CYP450 inhibitor**.
- Since the patient is also on an **oral anticoagulant** for atrial fibrillation, inhibition of CYP450 enzymes can reduce the metabolism of the anticoagulant, leading to **increased anticoagulant effect** and subsequent bleeding and bruising.
*Sulfation*
- **Sulfation** is a phase II metabolic reaction that converts compounds into more polar and excretable forms, but omeprazole primarily affects phase I metabolism involving CYP450 enzymes.
- While sulfation can be important for the metabolism of some drugs, it is not the primary process inhibited by omeprazole to cause increased bleeding with oral anticoagulants.
*Filtration*
- **Filtration** is a renal process and not a metabolic enzyme pathway affected by omeprazole.
- Omeprazole's interaction with anticoagulants mainly occurs through hepatic metabolism, not renal filtration.
*Acetylation*
- **Acetylation** is a phase II metabolic reaction, primarily carried out by **N-acetyltransferases**.
- Omeprazole is primarily known to interact with **CYP450 enzymes** (phase I metabolism) rather than N-acetyltransferases.
*Glucuronidation*
- **Glucuronidation** is a phase II metabolic reaction involving **UGT enzymes** that typically inactivates and increases the excretion of drugs.
- While important for drug metabolism, omeprazole's primary drug interactions leading to increased anticoagulant effects are via **CYP450 inhibition** (phase I metabolism), not directly through glucuronidation.
Question 289: A 55-year-old man comes to the physician because of a 2-month history of gradually worsening pain and burning in his feet that is impairing his ability to sleep. He also has a non-healing, painless ulcer on the bottom of his right toe, which has been progressively increasing in size despite the application of bandages and antiseptic creams at home. He has a 7-year history of type II diabetes mellitus treated with oral metformin. He also has narrow-angle glaucoma treated with timolol eye drops and chronic back pain due to a motorcycle accident a few years ago, which is treated with tramadol. Vital signs are within normal limits. Physical examination shows a 3-cm, painless ulcer on the plantar surface of the right toe. The ulcer base is dry, with no associated erythema, edema, or purulent discharge. Neurological examination shows loss of touch, pinprick sensation, proprioception, and vibration sense of bilateral hands and feet. These sensations are preserved in the proximal portions of the limbs. Muscle strength is normal. Bilateral ankle reflexes are absent. A diabetic screening panel is done and shows a fasting blood sugar of 206 mg/dL. An ECG shows a left bundle branch block. Which of the following is the most appropriate next step in the management of this patient's pain?
A. Oxycodone
B. Pregabalin (Correct Answer)
C. Injectable insulin
D. Amitriptyline
E. Ulcer debridement
Explanation: ***Pregabalin***
- This patient presents with symptoms highly suggestive of **diabetic peripheral neuropathy**, including burning pain in the feet, a painless neuropathic ulcer, and loss of sensation in a stocking-glove distribution with absent ankle reflexes. **Pregabalin** is a first-line agent for neuropathic pain.
- It works by binding to the **α2δ subunit of voltage-gated calcium channels**, reducing the release of excitatory neurotransmitters.
- Pregabalin is **preferred over amitriptyline** in this patient due to his cardiac conduction abnormality (LBBB) and age-related concerns with anticholinergic effects.
*Oxycodone*
- **Opioids like oxycodone** are generally not recommended as first-line treatment for chronic neuropathic pain due to concerns about tolerance, dependence, and side effects.
- While it may provide some pain relief, the **risks often outweigh the benefits** for long-term management of diabetic neuropathy.
*Injectable insulin*
- Poorly controlled **diabetes mellitus** is the underlying cause for the patient's neuropathy and ulcer, and optimizing glycemic control (e.g., with insulin) is crucial for preventing progression and complications.
- However, **injectable insulin** is not a direct treatment for the symptomatic **neuropathic pain or burning sensation** the patient is experiencing.
- While important for long-term management, it does not address the immediate complaint of pain.
*Amitriptyline*
- **Amitriptyline**, a tricyclic antidepressant, is another first-line medication for **neuropathic pain**.
- However, it is **relatively contraindicated** in this patient due to his **left bundle branch block (LBBB)**, as tricyclic antidepressants can worsen cardiac conduction abnormalities and increase the risk of arrhythmias.
- Additionally, as an **anticholinergic** agent, it is generally less preferred in older patients due to potential side effects like urinary retention, constipation, dry mouth, dizziness, and confusion.
*Ulcer debridement*
- **Ulcer debridement** is an important step in the management of the non-healing ulcer to promote healing and prevent infection.
- While crucial for ulcer management, it does not directly address the primary complaint of **burning neuropathic pain** in the feet.
Question 290: A 28-year-old woman presents with increased facial hair growth. She says she noticed a marked growth and darkening of hair on her face and feels embarrassed. Past medical history is significant for asthma, well-controlled by medication, and epilepsy diagnosed 6 months ago, managed with phenytoin. Her other medications are albuterol, beclomethasone, a daily multivitamin, and a garlic supplement. The patient denies any smoking history, alcohol or recreational drug use. Family history is significant for asthma in her father. Review of systems is positive for occasional diplopia. Her pulse is 75/min, respiratory rate is 15 /min, and blood pressure is 110/76 mm Hg. Her body mass index (BMI) is 24 kg/m2. On physical examination, she appears healthy in no apparent distress. There are excessive facial hair growth and enlarged gums. The remainder of the examination is unremarkable. Which of the following medications is most likely responsible for this patient's symptoms?
A. Garlic supplement
B. Phenytoin (Correct Answer)
C. Albuterol
D. Beclomethasone
E. Multivitamin
Explanation: ***Phenytoin***
- Phenytoin is a known cause of **hirsutism** (excessive facial hair growth) and **gingival hyperplasia** (enlarged gums).
- The patient's recent diagnosis of **epilepsy** and subsequent treatment with phenytoin directly link her symptoms to this medication.
*Garlic supplement*
- Garlic supplements are generally associated with beneficial effects such as cardiovascular health and immune support.
- They are **not known** to cause hirsutism or gingival hyperplasia.
*Albuterol*
- Albuterol is a **beta-2 adrenergic agonist** used for asthma relief, primarily causing bronchodilation.
- Its common side effects include tremor, tachycardia, and headaches, but **not hirsutism or gingival hyperplasia**.
*Beclomethasone*
- Beclomethasone is an **inhaled corticosteroid** used to manage asthma and reduce airway inflammation.
- While systemic corticosteroids can have various side effects, inhaled forms have fewer systemic effects, and neither type causes **hirsutism** or **gingival hyperplasia**.
*Multivitamin*
- Multivitamins provide essential vitamins and minerals, and generally do not cause adverse effects unless consumed in excessive amounts.
- They are **not associated** with hirsutism or gingival hyperplasia.